We tested this idea by first determining the effectiveness of [111In]In-Bn-DTPA-PEG2K-trastuzumab-AuNPs for decreasing the CS of HER2-positive SK-BR-3 and MDA-MB-361 human BC cells in vitro, and for inhibiting the growth of s.c. MDA-MB-361 tumours in vivo in mice (Cai et al. 2016). The gene discussed is ERBB2; the disease is breast cancer.